Synopsis
Make defensible, person-centred psychotropic decisions through conception, pregnancy, birth and breastfeeding by separating illness risk from medicine exposure, using indication-specific evidence, planning neonatal observation and preserving effective treatment when clinically necessary.
- Ask what the medicine treats, whether it works, what happened during previous withdrawal, and which alternatives failed before comparing reproductive safety data.
- NICE recommends the lowest-risk suitable medicine, the lowest effective rather than ineffective dose, and monotherapy where possible, while accounting for previous response.
- A pregnancy registry signal is not the same as individual causation; explain background outcome rates, absolute increments, evidence limits and illness-related harms in understandable numbers where available.
- Do not switch a stable effective antidepressant solely because another drug is generally preferred for breastfeeding; SPS prioritises maternal symptom control and individual infant assessment.
- Valproate carries stringent MHRA reproductive restrictions, including Pregnancy Prevention Programme requirements for women and girls able to have children and current initiation safeguards for patients younger than 55.
- Lithium needs gestation-specific plasma monitoring, hydration and labour instructions; breastfeeding decisions require specialist advice because NICE advises avoidance and SPS describes only closely supervised selected use.
- For a full-term healthy breastfed infant, SPS identifies sertraline or paroxetine as preferred SSRIs and quetiapine or haloperidol as preferred agents within their antipsychotic classes, but previous response remains central.
- Tell maternity and neonatal teams about late-pregnancy exposure so the newborn receives a full assessment and monitoring tailored to possible adaptation, withdrawal, toxicity or feeding difficulty.
- Sedating medicines, alcohol, smoking, recreational drugs, infant prematurity and bed sharing can combine risk; counselling must cover the whole situation rather than medicine transfer alone.
- Document one accountable prescriber, the intended dose, monitoring, planned birth actions, feeding discussion, infant observations and what the patient should do if pregnancy or illness occurs.
Key red flags
A newly positive pregnancy test while taking valproate, lithium or another medicine needing specialist review requires prompt coordinated advice, without unsupervised sudden withdrawal.
Fever, clonus, hyperreflexia, autonomic instability and agitation after serotonergic exposure suggests serotonin toxicity and requires urgent medical assessment.
Vomiting, coarse tremor, ataxia, confusion or drowsiness in a person taking lithium may indicate toxicity, particularly with dehydration or an interacting medicine.
A breastfed infant who is unusually sleepy, feeds poorly, has fewer wet nappies, abnormal tone, tremor or inadequate weight gain needs prompt paediatric and medicines review.
Emergent mania, psychosis, suicidal intent or rapid functional collapse after reducing medication outweighs a routine reproductive-medicines discussion and needs same-day crisis care.
Investigation priorities
Confirm medicine, formulation, dose, timing, indication, adherence, over-the-counter products, supplements and substance exposure.
Management branches
A psychotropic medicine is being considered, continued or changed during pregnancy or breastfeeding.
- Verify diagnosis, severity, previous response, withdrawal history, relapse consequences and all current exposures before discussing reproductive data.
- Compare continuation, optimisation, switching and stopping using absolute outcome information, illness risk, gestational timing and the person's informed priorities.
- Agree the lowest-risk effective strategy, usually limiting polypharmacy where feasible, with a taper or cross-titration schedule and named review date when changing treatment.